HXBM — Helix BioMedix Share Price
Last trade - 00:00- $1.61m
- $1.40m
- $1.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.4 | ||
| Price to Tang. Book | 1.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -205.02% | ||
| Return on Equity | -122.53% | ||
| Operating Margin | -117.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2007 | 2008 | 2009 | 2010 | 2011 | 2012E | 2013E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.46 | 0.56 | 0.39 | 0.85 | 1.89 | n/a | n/a | 92.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Helix BioMedix, Inc. is a biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum (XP). The Company is in the preclinical stage of development and intends to file for orphan drug designation prior to entering the clinical development pathway. Its legacy business consists of an proprietary library of patented bioactive peptides. Its lead drug development candidate, HB4208, is a polypeptide DNA deoxyribonucleic (DNA) damage response (DDR) enzyme for topical treatment of the rare genetic disorder (orphan disease) XP. Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. It is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. It is also engaged in the treatment of skin conditions.
Directors
- R Beatty PRE (63)
- Robin Carmichael COO (56)
- Randall Caudill IND (65)
- John Clifford IND (69)
- Richard Cohen IND (66)
- Lawrence Jones IND (65)
- Jeffrey Miller IND (69)
- Barry Seidman IND (66)
- Last Annual
- December 31st, 2011
- Last Interim
- September 30th, 2012
- Incorporated
- November 1st, 2000
- Public Since
- July 25th, 2000
- No. of Shareholders
- 787
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 224,708
- Address
- 19125 Northcreek Parkway Suite 120, BOTHELL, 98021
- Web
- https://helixbiomedix.com/
- Phone
- +1 4254028400
- Auditors
- KPMG LLP
Similar to HXBM
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 03:03 UTC, shares in Helix BioMedix are trading at $7.18. This share price information is delayed by 15 minutes.
Shares in Helix BioMedix last closed at $7.18 and the price had moved by -69.14% over the past 365 days. In terms of relative price strength the Helix BioMedix share price has underperformed the S&P500 Index by -71.17% over the past year.
There is no consensus recommendation for this security.
Find out moreHelix BioMedix does not currently pay a dividend.
Helix BioMedix does not currently pay a dividend.
Helix BioMedix does not currently pay a dividend.
To buy shares in Helix BioMedix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.18, shares in Helix BioMedix had a market capitalisation of $1.61m.
Here are the trading details for Helix BioMedix:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HXBM
Based on an overall assessment of its quality, value and momentum Helix BioMedix is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Helix BioMedix. Over the past six months, its share price has underperformed the S&P500 Index by -58.94%.
As of the last closing price of $7.18, shares in Helix BioMedix were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Helix BioMedix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Helix BioMedix's management team is headed by:
- R Beatty - PRE
- Robin Carmichael - COO
- Randall Caudill - IND
- John Clifford - IND
- Richard Cohen - IND
- Lawrence Jones - IND
- Jeffrey Miller - IND
- Barry Seidman - IND